Dengue and dengue vaccines

Journal of Infectious Diseases

Volumn 191, Issue 5, 2005, Pages 650-653

  Edelman, Robert ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

AEDES AEGYPTI; DENGUE; DENGUE VIRUS; EDITORIAL; ENDEMIC DISEASE; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL;

ADULT; CHILD; DENGUE; DENGUE VIRUS; HIV INFECTIONS; HUMANS; INFANT; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; VIRAL VACCINES;

EID: 13944255363     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427784     Document Type: Editorial

References (45)

1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100-3.
2. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990; 3:376-96.
3. Jelinek T, Muhlberger N, Harms G, et al. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35:1047-52.
4. DeRoeck D, Deen J, Clemens JD. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine 2003; 22:121-9.
5. Almond J, Clemens J, Engers H, et al. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. Vaccine 2002; 20:3043-6.
6. Sabin A. Research on dengue in World War II. Amer J Trop Med 1952; 1:30-50.
7. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172-80.
8. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970; 42:311-28.
9. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42: 179-84.
10. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
11. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239: 476-81.
12. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001; 260:145-69.
13. Bancroft WH, Scott RM, Eckels KH, et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 1984; 149:1005-10.
14. Bancroft WH, Top FH, Eckels KH, Anderson JH, McCown JM, Russell PK. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun 1981; 31:698-703.
15. Hoke CH, Malinoski FJ, Eckels KH, et al. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 1990; 43:219-26.
16. McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36:435-12.
17. Halstead SB, Eckels KH, Putvatana R, Larsen LK, Marchette NJ. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am J Trop Med Hyg 1984; 33:679-83.
18. Halstead SB, Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003; 69:5-11.
19. Eckels KH, Scott RM, Bancroft WH, et al. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 1984; 33:684-9.
20. Edelman R, Tacket CO, Wasserman SS, et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 1994; 170:1448-55.
21. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18(Suppl 2):44-7.
22. Kanesa-Thasan N, Edelman R, Tacket CO, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69:17-23.
23. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
24. Kanesa-Thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-88.
25. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31.
26. Sabchareon A, Lang I, Chauthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Ped Infect Dis J 2004; 23:99-109.
27. Sabchareon A, Lang J, Chauthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccine; in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Ttop Med Hyg 2002; 66:264-72.
28. Durbin AP, Whitehead SS, McArthur J, et al. rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-8 (in this issue).
29. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:3930-7.
30. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001; 65:405-13.
31. Troyer JM, Hanley KA, Whitehead SS, et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001; 65:414-9.
32. Anderson R, King AD, Innis BL. Correlation of E protein binding with cell susceptibility to dengue 4 virus infection. J Gen Virol 1992; 73:2155-9.
33. Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 2004; 70:89-97.
34. Guirakhoo F, Pugachev K, Arroyo J, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:146-59.
35. Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004; 22:3722-6.
36. Johnson BW, Chambers TV, Crabtree MB, Arroyo J, Monath TP, Miller BR. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol 2003; 17:235-43.
37. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18.
38. Arroyo J, Miller C, Catalan J, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78:12497-507.
39. Putnak R, Barvir DA, Burrous JM, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174:1176-84.
40. Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol 2003; 33: 567-82.
41. Trent DW, Grant JA, Monath TP, Manske CL, Corina M, Fox GE. Genetic variation and microevolution of dengue 2 virus in Southeast Asia. Virology 1989; 172:523-35.
42. Trent DW, Grant JA, Rosen L, Monath TP. Genetic variation among dengue 2 viruses of different geographic origin. Virology 1983; 128:271-84.
43. Watt G, Kantipong P, Jongsakul K. Decrease in human immunodeficiency virus type 1 load during acute dengue fever. Clin Infect Dis 2003; 36:1067-9.
44. Guy B, Chanthavanich P, Gimenez S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:3563-74.
45. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002; 360:1243-5.